Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway

被引:29
作者
Niimi, M
Shirasugi, N
Ikeda, Y
Kan, S
Takami, H
Hamano, K
机构
[1] Teikyo Univ, Dept Surg 1, Itabashi Ku, Tokyo 1738605, Japan
[2] Yamaguchi Univ, Dept Surg 1, Ube, Yamaguchi 7558505, Japan
关键词
D O I
10.1097/00007890-200111150-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Dendritic cells can mount immune response as competent antigen presenting cells. Recently, it has been reported that immature dendritic cells induce prolongation of allograft survival. However, the ability of mature dendritic cells to induce operational tolerance is unclear. Therefore, in this study, we examined the ability of splenic mature dendritic cells to induce operational tolerance to fully allogeneic antigens using mouse heterotopic heart transplantation model. Methods. CBA (H2(k)) mice received i.v. injections with donor splenic dendritic cells or B cells in the absence or presence of monoclonal antibody (mAb) specific for CD40 ligand or CD80/CD86 2 weeks before transplantation of a C57BL/10 (H2(b)) heart. Results. When donor dendritic cells were injected i.v. 2 weeks before transplantation, rejection response was accelerated compared with that of naive mice [median survival time (MST) = 7 and 8 days, respectively]. However, when CD40 pathway was blocked by anti-CD40 ligand mAb, i.v. injection of donor dendritic cells but not B cells induced indefinite graft survival (MST > 100 and 20 days, respectively). Mice treated with anti-CD40 ligand mAb alone rejected their grafts with a MST of 18 days. Intravenous injection of donor dendritic cells and B cells in combination with anti-CD80/CD86 mAbs was less effective to induce graft prolongation (MST = 9.5 and 13 days, respectively). Conclusions. Therefore, under blockade of CD40 pathway, mature dendritic cells were tolerogens in vivo independent of CD80/86 pathways.
引用
收藏
页码:1556 / 1562
页数:7
相关论文
共 37 条
[21]  
Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO
[22]  
2-8
[23]   Resting B cells as tolerogens in vivo but only for minor histocompatibility antigens - Evidence for activation of resting B cells in vivo [J].
Niimi, M ;
Roelen, DL ;
Wong, W ;
Hara, M ;
Morris, PJ ;
Wood, KJ .
TRANSPLANTATION, 1997, 64 (09) :1330-1335
[24]   Immunogenic (MHC class II+) cells are able to induce unresponsiveness when delivered with anti-CD4 monoclonal antibody [J].
Niimi, M ;
Morris, PJ ;
Wood, KJ .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :2450-2450
[25]   Intrathymic inoculation of donor B coils prolongs cardiac allograft survival by non-deletional mechanisms [J].
Niimi, M ;
Morris, PJ ;
Wood, KJ .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :94-94
[26]   CD40 and its ligand in host defense [J].
Noelle, RJ .
IMMUNITY, 1996, 4 (05) :415-419
[27]   CONTRIBUTION OF DENDRITIC CELLS TO STIMULATION OF THE MURINE SYNGENEIC MIXED LEUKOCYTE REACTION [J].
NUSSENZWEIG, MC ;
STEINMAN, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 151 (05) :1196-1212
[28]   DENDRITIC CELLS USE MACROPINOCYTOSIS AND THE MANNOSE RECEPTOR TO CONCENTRATE MACROMOLECULES IN THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II COMPARTMENT - DOWN-REGULATION BY CYTOKINES AND BACTERIAL PRODUCTS [J].
SALLUSTO, F ;
CELLA, M ;
DANIELI, C ;
LANZAVECCHIA, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :389-400
[29]   Dendritic cells as adjuvants for immune-mediated resistance to tumors [J].
Schuler, G ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1183-1187
[30]   Models of T cell anergy: Is there a common molecular mechanism? [J].
Schwartz, RH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :1-8